Navigation Links
Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor,AP 12009 to be Presented

REGENSBURG, Germany, May 10th, 2007 - Antisense Pharma today announced, that the abstract entitled “Preliminary Results of a Phase I/II-Study in Pancreatic Carcinoma, Malignant Melanoma, and Colorectal Carcinoma with the TGF-beta2 Inhibitor AP 12009” has been selected for poster presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held in Chicago, Illinois, U.S.A, from June 1st - 5th.

In the Phase I/II-trial the antisense drug AP 12009 is administered intravenously in patients with either pancreatic carcinoma (stage IVA/IVB), metastatic melanoma (stage III/IV), or advanced colorectal carcinoma (stage III/IV) as a 7-day continuous infusion every other week. “The first milestone of the study has been achieved, as the maximum tolerated dose was determined with this treatment schedule”, explains Hubert Heinrichs, M.D., Ph.D., Chief Medical Officer at Antisense Pharma. Patient recruitment is still ongoing in study sites in Germany as further dose escalations with a modified dosing schedule are now performed. The design of the study, first efficacy and safety data will be presented at the poster presentation (Poster Board No. AA5, Abstract ID 4607) on June 4th 2007 from 8:00 a.m. to 12:00 p.m. in the session “Gastrointestinal (Noncolorectal) Cancer”. Prof. Thomas Seufferlein, Vice Head of the Department of Internal Medicine at the University of Ulm and Principal Investigator of the Phase I/II-Study will be available for questions from 11:00 a.m. to 12:00 p.m. at the poster in Hall A2 on Level 3 of McCormick Place South Building.

About Antisense Pharma

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization.


'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Phase data Systemic Application the TGF beta2 inhibitor Presented
(Date:7/31/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) ... and delivery systems for the eye today reported revenue ... $20.0 million, a 10% increase over $18.2 million reported ... currency basis, revenues grew 11% during the second quarter ... The effect of foreign currency exchange reduced sales by ...
(Date:7/31/2014)... 31, 2014 Xencor Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... reported financial results for the second quarter ended June ... business highlights. "In the second quarter, ... Society 2014 International Conference (ATS) demonstrating three novel ...
(Date:7/31/2014)... , July 31, 2014  Alexza Pharmaceuticals, Inc. ... update on its pipeline and new product development ... to initiate a Phase 2a study of AZ-002 ... for the management of patients with acute repetitive ... Staccato -based product candidates for development - AZ-008 ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6
... patients,have complained for years about the mental fog ... Virginia University, researchers have discovered,that injections of N-acetyl ... that breast cancer chemotherapy drugs sometimes induce., ... September issue of the,journal Metabolic Brain Disease, rats ...
... W.Va., Sept. 5 A team of,researchers at ... from,India and Pakistan take on the habits of ... among male immigrants and breast cancer,among females., ... many reasons, but,environmental factors and lifestyle play a ...
Cached Medicine Technology:Study Suggests a Possible Way to Offset Chemobrain Memory Loss 2Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2
(Date:7/31/2014)... 31, 2014 Parker Waichman, LLP, a ... cases, comments that whistleblowers are a critical component of ... activities that may cause harm to consumers and may ... Whistleblower Appreciation Day. , According to a 2013 report ... Senate declared "National Whistleblower Appreciation Day" on July 30, ...
(Date:7/31/2014)... 31, 2014 Etymotic Research, an ... new sponsorship of the DrumLine Battle® series of ... hearing protection products ETY•Plugs® and Music•PRO® electronic earplugs. ... harmful effects of high-level sound. Etymotic will be ... the Drum Corps International Championships on August 7-9, ...
(Date:7/31/2014)... News) -- Many black women put concerns about their ... It,s estimated by the U.S. Centers for Disease Control ... in the United States are overweight or obese. Yet ... having to have their hair restyled or restraightened, the ... However, the researchers also noted a shift toward more ...
(Date:7/31/2014)... Rich Dad® Education , a leader ... benefit Habitat for Humanity. The yard sale was a success. ... of the proceeds donated to Habitat for Humanity of Lee ... the event were donated to the Habitat for Humanity ReStore ... Florida 33903. , Of the over $650, roughly $30 ...
(Date:7/31/2014)... an algorithm aimed to diagnose pediatric patients with ... (CT) scans, without affecting diagnostic accuracy, Mayo Clinic ... recently published in the journal Surgery . ... of acute abdominal pain in children. Appendicitis occurs ... pus. CT scans are often used to diagnose ...
Breaking Medicine News(10 mins):Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 2Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 4Health News:Etymotic Research Becomes The Official Hearing Protection Sponsor Of DrumLine Battle 2Health News:Hairdo Trumps Exercise for Many Black Women, Study Finds 2Health News:Rich Dad Education Charity Yard Sale to Benefit Habitat for Humanity of Lee and Hendry Counties a Success 2
... announcement of the Genetics & Public Policy Center ... May 5 To "get personalized medicine right," ... need to "create and implement a reasonable and ... advanced medical diagnostics, a diverse coalition of more ...
... and cardiovascular disease in obese women, but getting started ... study by researchers at the Swedish medical university Karolinska ... more women to exercise to and from work. ... for helping populations at risk of heart disease and ...
... In support of World Asthma Day, ... partnership with Direct Relief International, a nonprofit humanitarian ... of QVAR(R) (Beclomethasone HFA), an Inhaled Corticosteroid (ICS) ... will distribute the medication to economically disadvantaged and ...
... Bates County Memorial Hospital (BCMH), a ... the MedGenix financial and patient management system. The MedGenix ... cycle management and financial accounting modules. The MedGenix ... Systems (CHS), based in Springfield, MO. Founded in 1992, ...
... goals to expand nationwide, Wellspring recently ... Bill will spearhead the newly formed Network Development Division that ... 2010. He is responsible for making Wellspring a household name ... Fortune 100 senior executive with healthcare, insurance and leading technology ...
... May 5 Air Products (NYSE: APD ... U.S. home infusion therapy services business and some elements ... OptionCare Enterprises, Inc., a subsidiary of Walgreen Co. ... Air Products, ownership interests in certain of the companies ...
Cached Medicine News:Health News:Overhaul of Genetic and Other Advanced Diagnostic Testing Regulations Necessary for Personalized Medicine, HHS Secretary Told 2Health News:Overhaul of Genetic and Other Advanced Diagnostic Testing Regulations Necessary for Personalized Medicine, HHS Secretary Told 3Health News:Extra support helps obese women cycle to and from work 2Health News:Teva Respiratory Supports World Asthma Day by Providing FREE QVAR(R) to Those Who Need It Most 2Health News:Teva Respiratory Supports World Asthma Day by Providing FREE QVAR(R) to Those Who Need It Most 3Health News:Teva Respiratory Supports World Asthma Day by Providing FREE QVAR(R) to Those Who Need It Most 4Health News:Teva Respiratory Supports World Asthma Day by Providing FREE QVAR(R) to Those Who Need It Most 5Health News:MedGenix Financial Information System Selected by Bates County Memorial Hospital 2Health News:Wellspring Hires William Young and Prepares for Nationwide Expansion 2Health News:Air Products Sells Major Portion of U.S. Healthcare Operations to Walgreens 2
... The Leica RM2235 is a robust ... of primarily biological specimens embedded in ... backlash-free precision micrometer feed system ensures ... even when sectioning harder tissues. The ...
... biomedical and industrial applications, the Leica SM2400 ... of applications in all laboratories where paraffin ... sectioned. Its sturdy construction lends it qualities ... features of the system, such as a ...
... Automatic microtome with vibrating blade for fixed and ... as for non-biological specimen in material science ... of blade amplitude between 0,1 and 1,2 mm ... parameters can be set independently from each other. ...
... EC 350 consists of two modular units. ... surface and reaches a temperature of -15C. ... reservoir, heated dispenser nozzle, heated work surface, ... separate heated compartments for molds and cassettes. ...
Medicine Products: